At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 652 enrolled
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Zanubrutinib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In Brief
A Phase 3 clinical trial evaluating Zanubrutinib and Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Completed, enrolled 652 participants across 115 sites in 15 countries.
Detailed Summary
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, China, Czechia, France, Germany, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionAug 2022
Study CompletionFeb 2024
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartNov 1, 2018
Primary CompletionAug 8, 2022
Study CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.7 years ago
Interventions
Zanubrutinibdrug
160 mg orally twice daily
Ibrutinibdrug
Ibrutinib 420 mg orally once daily